{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T08:12:24Z","timestamp":1778314344319,"version":"3.51.4"},"reference-count":47,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2375,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Depress. Anxiety"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1002\/da.20460","type":"journal-article","created":{"date-parts":[[2009,1,5]],"date-time":"2009-01-05T22:50:02Z","timestamp":1231195802000},"page":"259-265","source":"Crossref","is-referenced-by-count":30,"title":["Natural remedies for anxiety disorders: potential use and clinical applications"],"prefix":"10.1155","volume":"26","author":[{"given":"Gustavo","family":"Kinrys","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliza","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ethan","family":"Rothstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","reference":[{"key":"10.1002\/da.20460-BIB1","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1001\/archfami.6.2.149","article-title":"Clinical practice guidelines in complementary and alternative medicine. An analysis of opportunities and obstacles. Practice and policy guidelines panel","volume":"6","author":"National Institutes of Health Office of Alternative Medicine","year":"1997","journal-title":"Arch Fam Med"},{"key":"10.1002\/da.20460-BIB2","first-page":"353","article-title":"Modulation of cytokine expression by hypericum extract","volume":"12","author":"Thiele","year":"1993","journal-title":"Nevenheilkunde"},{"key":"10.1002\/da.20460-BIB3","first-page":"357","article-title":"Effects of hypericum extract on the expression of serotonin receptors","volume":"12","author":"Muller","year":"1993","journal-title":"Nervenheilkunde"},{"key":"10.1002\/da.20460-BIB4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2007-979530","article-title":"Effects of long-term administration of hypericum extracts on the affinity and density of the central sertonergic 5-HT1 A and 5-HT2 A receptors","volume":"30","author":"Teufel-Mayer","year":"1997","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/da.20460-BIB5","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-662-09666-6","volume-title":"Rational phytotherapy","author":"Schulz","year":"2004"},{"key":"10.1002\/da.20460-BIB6","first-page":"2249","article-title":"St. John's wort","volume":"72","author":"Lawvere","year":"2005","journal-title":"Am Fam Physician"},{"key":"10.1002\/da.20460-BIB7","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1177\/089198879400701s14","article-title":"Inhibition of MAO and COMT by hypericum extracts and hypericin","volume":"7","author":"Thiede","year":"1994","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"10.1002\/da.20460-BIB8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1592\/phco.20.6.568.35152","article-title":"Consumer use of St. John's wort: a survey on effectiveness, safety, and tolerability","volume":"20","author":"Beckman","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1002\/da.20460-BIB9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(99)06457-0","article-title":"Herb-drug interactions","volume":"355","author":"Fugh-Berman","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/da.20460-BIB10","first-page":"1285","article-title":"St. John's wort-venlafaxine interaction","volume":"29","author":"Prost","year":"2000","journal-title":"Presse Med"},{"key":"10.1002\/da.20460-BIB11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1055\/s-2007-979346","article-title":"St John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy","volume":"31","author":"Laakmann","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/da.20460-BIB12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-2007-979345","article-title":"Pharmacodynamic effects of two different hypericum extracts in healthy volunteers measured by quantitative EEG","volume":"31","author":"Schellenberg","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/da.20460-BIB13","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1211\/0022357991772132","article-title":"Isolation, purity analysis and stability of hyperforin as a standard material from Hypericum perforatum L","volume":"51","author":"Orth","year":"1999","journal-title":"J Pharm Pharmacol"},{"key":"10.1002\/da.20460-BIB14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/01.jcp.0000088921.02635.13","article-title":"St. John's wort in Generalized Anxiety Disorder: three more case reports","volume":"23","author":"Kobak","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.20460-BIB15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.jcp.0000150227.61501.00","article-title":"St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study","volume":"25","author":"Kobak","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.20460-BIB16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.v61n0806","article-title":"An open-label trial of St. John's wort (Hypericum perforatum) in obsessive compulsive disorder","volume":"61","author":"Taylor","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1002\/da.20460-BIB17","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00004850-200511000-00003","article-title":"St. John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study","volume":"20","author":"Kobak","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/da.20460-BIB18","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00004714-200112000-00026","article-title":"St. John's wort in generalized anxiety disorder: three case reports","volume":"21","author":"Davidson","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1002\/da.20460-BIB19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF02247480","article-title":"Kavapyrone enriched extract from Pipermethysticum as modulator of the GABA binding site in different regions of rat brain","volume":"116","author":"Jussofie","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1002\/da.20460-BIB20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1055\/s-2002-36338","article-title":"Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation","volume":"68","author":"Yuan","year":"2002","journal-title":"Planta Med"},{"key":"10.1002\/da.20460-BIB21","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0028-3908(95)00163-8","article-title":"(+\/\u2212)-Kavain inhibits the veratridine- and KCl-induced increase in intracellular Ca2+ and glutamate-release of rat cerebrocortical synaptosomes","volume":"35","author":"Gleitz","year":"1996","journal-title":"Neuropharmacology"},{"key":"10.1002\/da.20460-BIB22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0014-2999(96)00550-X","article-title":"Anticonvulsive action of (+\/\u2212)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites","volume":"315","author":"Gleitz","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1002\/da.20460-BIB23","first-page":"CD003383","article-title":"Kava extract for treating anxiety","volume":"1","author":"Pittler","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1002\/da.20460-BIB24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ptr.1609","article-title":"Meta-analysis of the efficacy of the acetonic kava-kava extract WS 1490 in patients with non-psychotic anxiety disorders","volume":"19","author":"Witte","year":"2005","journal-title":"Phytother Res"},{"key":"10.1002\/da.20460-BIB25","doi-asserted-by":"crossref","first-page":"848, 850","DOI":"10.1017\/S109285290000167X","article-title":"Adverse-effect profile of kava","volume":"6","author":"Connor","year":"2001","journal-title":"CNS Spectr"},{"key":"10.1002\/da.20460-BIB26","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00004850-200609000-00001","article-title":"Kava in generalized anxiety disorder: three placebo-controlled trials","volume":"21","author":"Connor","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1002\/da.20460-BIB27","volume-title":"British herbal compendium","volume":"1","year":"1992","unstructured":"BradleyPR, editor. British herbal compendium, Vol. 1. Bournemouth: British Herbal Medicine Association; 1992."},{"key":"10.1002\/da.20460-BIB28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0378-8741(01)00339-7","article-title":"Anti-anxiety studies on extracts of Passiflora incarnata Linneaus","volume":"78","author":"Dhawan","year":"2001","journal-title":"J Ethnopharmacol"},{"key":"10.1002\/da.20460-BIB29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0378-8741(02)00086-7","article-title":"Suppression of alcohol-cessation-oriented hyper-anxiety by the benzoflavone moiety of Passiflora incarnata Linneaus in mice","volume":"81","author":"Dhawan","year":"2002","journal-title":"J Ethnopharmacol"},{"key":"10.1002\/da.20460-BIB30","first-page":"215","article-title":"Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic","volume":"6","author":"Dhawan","year":"2003","journal-title":"J Pharm Pharmaceut Sci"},{"key":"10.1002\/da.20460-BIB31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2710.2001.00367.x","article-title":"Passionflower in the treatment of Generalized Anxiety Disorder: a pilot double-blind randomized controlled trial with oxazepam","volume":"26","author":"Akhondzadeh","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"10.1002\/da.20460-BIB32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00004714-200106000-00014","article-title":"Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder","volume":"21","author":"Palatnik","year":"2001","journal-title":"J Clin Psychopharm"},{"key":"10.1002\/da.20460-BIB33","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1176\/ajp.152.7.1084","article-title":"Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder","volume":"152","author":"Benjamin","year":"1995","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20460-BIB34","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1176\/ajp.153.9.1219","article-title":"Inositol treatment of obsessive-compulsive disorder","volume":"153","author":"Fux","year":"1996","journal-title":"Am J Psychiatry"},{"key":"10.1002\/da.20460-BIB35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145799001546","article-title":"Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study","volume":"2","author":"Fux","year":"1999","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1002\/da.20460-BIB36","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-244X-4-30","article-title":"Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram","volume":"4","author":"Carey","year":"2004","journal-title":"BMC Psychiatry"},{"key":"10.1002\/da.20460-BIB37","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1213\/01.ANE.0000096189.70405.A5","article-title":"The gamma-aminobutyric acidergic effects of valerian and valerenic acid on rat brainstem neuronal activity","volume":"98","author":"Yuan","year":"2004","journal-title":"Anesth Analg"},{"key":"10.1002\/da.20460-BIB38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.molbrainres.2005.04.009","article-title":"Valerian extract and valerenic acid are partial agonists of the 5-HT5a receptor in vitro","volume":"138","author":"Dietz","year":"2005","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1002\/da.20460-BIB39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1055\/s-2007-1017047","article-title":"The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions","volume":"21","author":"Kohnen","year":"1988","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/da.20460-BIB40","first-page":"4659","article-title":"Therapy of symptoms of anxiety","volume":"41","author":"Panijel","year":"1985","journal-title":"Therapiewoche"},{"key":"10.1002\/da.20460-BIB41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0006-8993(02)03565-5","article-title":"Melatonin alters behavior and cAMP levels in nucleus accumbens induced by cocaine treatment","volume":"956","author":"Zhdanova","year":"2002","journal-title":"Brain Res"},{"key":"10.1002\/da.20460-BIB42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0091-3057(00)00302-6","article-title":"Melatonin reduces symptoms of acute nicotine withdrawal in humans","volume":"67","author":"Zhdanova","year":"2000","journal-title":"Pharm Biochem Behav"},{"key":"10.1002\/da.20460-BIB43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.euroneuro.2005.07.005","article-title":"Red cell membrane omega-3 fatty acids are decreased in nondepressed patients with social anxiety disorder","volume":"16","author":"Green","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1002\/da.20460-BIB44","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3956(03)00077-3","article-title":"A placebo-controlled cross-over trial of adjunctive EPA in OCD","volume":"38","author":"Fux","year":"2004","journal-title":"J Psychiatr Res"},{"key":"10.1002\/da.20460-BIB45","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2165\/00023210-199606060-00002","article-title":"S-adenosyl-methionine (ademethionine) in psychiatric disorders","volume":"6","author":"Spillmann","year":"1996","journal-title":"CNS Drugs"},{"key":"10.1002\/da.20460-BIB46","doi-asserted-by":"crossref","first-page":"1158S","DOI":"10.1093\/ajcn\/76.5.1158S","article-title":"Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence","volume":"76","author":"Mischoulon","year":"2002","journal-title":"Am J Clin Nutr"},{"key":"10.1002\/da.20460-BIB47","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1192\/bjp.150.5.724","article-title":"Switch mechanism in affective illness and oral S-adenosylmethionine (SAM)","volume":"150","author":"Carney","year":"1987","journal-title":"Br J Psychiatry"}],"container-title":["Depression and Anxiety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fda.20460","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/da.20460\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T13:03:33Z","timestamp":1671541413000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/da.20460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"URL":"https:\/\/doi.org\/10.1002\/da.20460","relation":{},"ISSN":["1091-4269","1520-6394"],"issn-type":[{"value":"1091-4269","type":"print"},{"value":"1520-6394","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}